Table 1 Patient characteristics at each tumor regression grade
| Â | TRG1 | TRG2 | TRG3 | P |
|---|---|---|---|---|
Number | ||||
| Â | 42 (33%) | 56 (44%) | 29 (23%) | Â |
Age at surgery | Â | Â | Â | 0.6208 |
|  | 65 (45–75) | 63 (41–75) | 64 (44–77) | |
Sex | Â | Â | Â | 0.7033 |
 Female | 5 (12%) | 10 (18%) | 5 (17%) |  |
 Male | 37 (88%) | 46 (82%) | 24 (83%) |  |
Tumor location | Â | Â | Â | 0.9615 |
 Upper | 9 (21%) | 12 (22%) | 5 (17%) |  |
 Middle | 20 (48%) | 27 (48%) | 13 (45%) |  |
 Lower | 13 (31%) | 17 (30%) | 11 (38%) |  |
Depth of invasion (cT) | Â | Â | Â | 0.5727 |
 T1 | 1 (2%) | 2 (4%) | 2 (7%) |  |
 T2 | 1 (2%) | 4 (7%) | 3 (10%) |  |
 T3 | 40 (95%) | 48 (86%) | 23 (79%) |  |
 T4 | 0 (0%) | 2 (4%) | 1 (4%) |  |
Lymph node metastasis (cN) | Â | Â | Â | 0.9545 |
 N0 | 4 (10%) | 4 (7%) | 3 (10%) |  |
 N1 | 24 (57%) | 33 (59%) | 19 (66%) |  |
 N2 | 13 (31%) | 18 (32%) | 7 (24%) |  |
 N3 | 1 (2%) | 1 (2%) | 0 (0%) |  |
Clinical stage (cStage) | Â | Â | Â | 0.8519 |
 IIA | 4 (10%) | 4 (7%) | 3 (10%) |  |
 IIB | 2 (5%) | 6 (11%) | 5 (17%) |  |
 IIIA | 22 (52%) | 26 (47%) | 13 (45%) |  |
 IIIB | 13 (31%) | 17 (30%) | 7 (24%) |  |
 IIIC | 1 (2%) | 3 (5%) | 1 (4%) |  |
Tumor differentiation | Â | Â | Â | 0.1977 |
 Not poorly | 38 (90%) | 49 (88%) | 22 (76%) |  |
 Poorly | 4 (10%) | 7 (12%) | 7 (24%) |  |
Tumor stage after NACRT |  |  |  | < 0.0001* |
 Downstaged | 16 (38%) | 30 (54%) | 28 (97%) |  |
 No change | 21 (50%) | 19 (34%) | 1 (3%) |  |
 Upstaged | 5 (12%) | 7 (13%) | 0 (0%) |  |
Recurrence | Â | Â | Â | 0.0113* |
 Presence | 22 (52%) | 22 (39%) | 5 (17%) |  |
 Absence | 20 (48%) | 34 (61%) | 24 (83%) |  |
Prognosis | Â | Â | Â | 0.0316* |
 Alive | 22 (52%) | 37 (66%) | 25 (86%) |  |
 Dead with ESCC | 18 (43%) | 15 (27%) | 3 (10%) |  |
 Dead with other diseases | 2 (5%) | 4 (7%) | 1 (4%) |  |